SUSANNAH GRAY - 23 May 2023 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role: Director
Signature: /s/ August Moretti as attorney-in-fact for Susannah Gray
Issuer symbol: FDMT
Transactions as of: 23 May 2023
Net transactions value: $0
Form type: 4
Filing time: 25 May 2023, 19:33:54 UTC
Previous filing: 04 May 2023
Next filing: 02 Jun 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FDMT	Stock Option (Right to Buy)	Award	$0	+22,500		$0.000000	22,500	23 May 2023	Common Stock	22,500	$17.98	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2	The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2024 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2026. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Content

Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2024 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2026. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).